DOI: 10.1097/inf.0000000000004062 ISSN:

Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study (miniSTONE-2)

Jeffery B. Baker, Stanley L. Block, Steven E. Cagas, Laura Burleigh Macutkiewicz, Colleen Collins, Mitra Sadeghi, Sriparna Sarkar, Sarah Williams
  • Infectious Diseases
  • Microbiology (medical)
  • Pediatrics, Perinatology and Child Health


miniSTONE-2 (NCT03629184) was a global, phase 3, randomized, controlled study that investigated the safety and efficacy of single-dose baloxavir marboxil in otherwise healthy children aged 1–<12 years and showed a positive risk-benefit profile. This post hoc analysis evaluated the safety and efficacy of baloxavir versus oseltamivir in children aged 5–11 years with influenza.


Children received single-dose baloxavir or twice-daily oseltamivir for 5 days. Safety was the primary objective. Efficacy and virological outcomes included time to alleviation of symptoms, duration of fever and time to cessation of viral shedding by titer. Data were summarized descriptively.


Ninety-four children aged 5–11 years were included (61 baloxavir and 33 oseltamivir). Baseline characteristics were similar between the groups. The incidence of adverse events was balanced and low in both treatment groups, with the most common being vomiting (baloxavir 5% vs. oseltamivir 18%), diarrhea (5% vs. 0%) and otitis media (0% vs. 5%). No serious adverse events or deaths occurred. Median (95% CI) time to alleviation of symptoms with baloxavir was 138.4 hours (116.7–163.4) versus 126.1 hours (95.9–165.7) for oseltamivir; duration of fever was comparable between groups [41.2 hours (23.5–51.4) vs. 51.3 hours (30.7–56.8), respectively]. Median time to cessation of viral shedding was shorter in the baloxavir group versus oseltamivir (1 vs. ≈3 days).


Safety, efficacy and virological results in children aged 5–11 years were similar to those from the overall study population aged 1–<12 years. Single-dose baloxavir provides an additional treatment option for pediatric patients aged 5–11 years with influenza.

More from our Archive